Chirfi Guindo - Net Worth and Insider Trading
Chirfi Guindo Net Worth
The estimated net worth of Chirfi Guindo is at least $803,104 dollars as of 2023-03-30. Chirfi Guindo is the Head of Glob Prod Strat & Com of Biogen Inc and owns about 2,919 shares of Biogen Inc (BIIB) stock worth over $803,104. Details can be seen in Chirfi Guindo's Latest Holdings Summary section.
Transaction Summary of Chirfi Guindo
Chirfi Guindo Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Chirfi Guindo owns 3 companies in total, including Biogen Inc (BIIB) , Merck & Co Inc (MRK) , and Merck & Co Inc (MRKPRB.PFD) .
Click here to see the complete history of Chirfi Guindo’s form 4 insider trades.
Insider Ownership Summary of Chirfi Guindo
|Ticker||Comapny||Transaction Date||Type of Owner|
|BIIB||Biogen Inc||2017-11-07||EVP Glob. Mkt Acc & Cust Innov|
|MRK||Merck & Co Inc||2022-07-01||Chief Marketing Officer|
|MRKPRB.PFD||Merck & Co Inc||2022-07-01||Chief Marketing Officer|
Chirfi Guindo Latest Holdings Summary
Chirfi Guindo currently owns a total of 1 stock. Chirfi Guindo owns 2,919 shares of Biogen Inc (BIIB) as of June 7, 2021, with a value of $803,104.
Latest Holdings of Chirfi Guindo
|Ticker||Comapny||Latest Transaction Date||Shares Owned||Current Price ($)||Current Value ($)|
Holding Weightings of Chirfi Guindo
Chirfi Guindo Form 4 Trading Tracker
According to the SEC Form 4 filings, Chirfi Guindo has made a total of 1 transactions in Biogen Inc (BIIB) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Biogen Inc is the sale of 3,087 shares on June 7, 2021, which brought Chirfi Guindo around $1 Million.
Insider Trading History of Chirfi Guindo
Chirfi Guindo Trading Performance
Chirfi Guindo Ownership Network
Ownership Network List of Chirfi Guindo
Ownership Network Relation of Chirfi Guindo
Chirfi Guindo Owned Company Details
What does Biogen Inc do?
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.
Who are the key executives at Biogen Inc?
Chirfi Guindo is the EVP Glob. Mkt Acc & Cust Innov of Biogen Inc. Other key executives at Biogen Inc include Head of Development Priya Singhal , director & President and CEO Christopher Viehbacher , and Head of Pharm Ops and Tech Nicole Murphy .
Biogen Inc (BIIB) Insider Trades Summary
Over the past 18 months, Chirfi Guindo made no insider transaction in Biogen Inc (BIIB). Other recent insider transactions involving Biogen Inc (BIIB) include a net sale of 5,610 shares made by Ginger Gregory , and a net sale of 5,532 shares made by Susan H Alexander .
In summary, during the past 3 months, insiders sold 0 shares of Biogen Inc (BIIB) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 11,142 shares of Biogen Inc (BIIB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 11,142 shares.
Biogen Inc (BIIB)'s detailed insider trading history can be found in Insider Trading Tracker table.
Biogen Inc Insider Transactions
Chirfi Guindo Mailing Address
Above is the net worth, insider trading, and ownership report for Chirfi Guindo. You might contact Chirfi Guindo via mailing address: C/o Biogen Inc., 225 Binney St., Cambridge Ma 02142.